Work

A phase 2 randomized trial of neoadjuvant enoblituzumab versus standard of care in men with high-risk localized prostate cancer: The help elucidate and attack longitudinally (HEAT) prostate cancer randomized study.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.tps5125

Authors: Eugene Shenderov, Angelo M De Marzo, Tamara L. Lotan, Hao Wang, Edward M. Schaeffer, Maha H. A. Hussain, Oliver Sartor, Paras H Shah, Ximing J Yang, Paari J. Murugan, Sounak Gupta, Christopher Warlick, Stephen A. Boorjian, Ashley Ross, Christian P. Pavlovich, Emmanuel S. Antonarakis, Mohamad E. Allaf

Institutions: Johns Hopkins University, Johns Hopkins Medicine, Northwestern University, Mayo Clinic, University of Minnesota, Masonic Cancer Center

Language: English

Topic: Prostate Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4399394497

Cites:

Cited by: 1

Related to: 10